Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Vigabatrin

Plain-language summaryIntrigue 69 / 100

Vigabatrin (Sabril) is a so-called suicide inhibitor of GABA transaminase, the enzyme that breaks down the brain’s main inhibitory neurotransmitter. The vinyl group on the molecule converts vigabatrin into a fake substrate that the enzyme attempts to process and is then permanently destroyed by; the only way the brain restores normal GABA breakdown is to manufacture new enzyme from scratch. The result is sustained and powerful elevation of brain GABA levels. It is uniquely effective in infantile spasms (a devastating early-childhood seizure disorder) and refractory complex partial seizures. The catch is severe and irreversible: roughly a third of patients develop permanent visual field constriction from retinal toxicity. That has restricted it to cases where no alternative works. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

The canonical irreversible GABA-T suicide inhibitor, clinically validated but mechanistically mature and toxicity-constrained

Vigabatrin has been in the clinic since 1989 in Europe, with US approval following in 2009. That timeline matters for how you read the score. This isnt a compound at the frontier of anything; it’s a compound that already did its frontier work decades ago and has been in routine use ever since.

The mechanism is genuinely clever, and worth understanding on its own terms. The vinyl group at the alpha-carbon turns vigabatrin into a substrate that GABA transaminase begins to process but can’t release. The result is irreversible covalent inactivation of the enzyme, with GABA degradation capacity only restored by de novo enzyme synthesis. That makes the pharmacodynamic window substantially longer than the plasma half-life of 5 to 13 hours would suggest. As a piece of chemical biology, suicide inhibition is elegant; as a research tool, the irreversibility is actually useful for experiments requiring sustained, stable GABA-T suppression without continuous re-dosing.

The clinical translational story is real and worth acknowledging directly. For infantile spasms, specifically West syndrome, the treatment options are limited and vigabatrin is one of them. The UKISS trial and the pivotal FDA registration studies, particularly for tuberous sclerosis-associated spasms, showed meaningful seizure suppression where many anticonvulsants fail. That’s a durable human signal, not a preclinical artifact.

The problem, and it’s not a minor one, is the retinal toxicity. Bilateral concentric visual field constriction in roughly 30 to 50 percent of long-term users. Irreversible. The FDA REMS program exists because of this, mandating baseline and periodic visual field testing. Current research thinking attributes the damage to GABA accumulation in retinal photoreceptors. For bench investigators, this means any animal model work with vigabatrin has to account for retinal off-target effects as a confound.

We think vigabatrin earns a library spot specifically as a reference probe. If your research program touches GABA metabolism, inhibitory circuit modulation, or mechanism-based enzyme inhibition as a chemical strategy, vigabatrin is the standard. No other approved compound does what it does to GABA-T. What it doesnt offer is novelty, a growing literature edge, or any real frontier signal. The mechanistic questions are settled, the clinical niche is narrow, and the toxicity profile constrains enthusiasm for new indication discovery. A serious bench scientist working on GABAergic biology needs this compound; a scientist looking for their next interesting target probably doesnt start here.

Novelty

22

Mechanism promise

42

In-category differentiation

60

Evidence quality

76

Translational signal

70

Research bench value

65

Rationale Vigabatrin earns solid evidence and translational scores given FDA approval, REMS-backed safety surveillance, and real infantile spasms efficacy, but novelty is low for a compound with 35-plus years of literature and a fully characterized mechanism; primary research value now sits in its role as the definitive irreversible GABA-T probe for GABAergic circuit and enzyme kinetics work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA transaminase inhibitor (irreversible)

An irreversible suicide inhibitor of GABA transaminase; uniquely effective in infantile spasms and refractory complex partial seizures, limited by retinal toxicity.

Abstract

Vigabatrin ((R/S)-4-aminohex-5-enoic acid; CAS 60643-86-9; molecular formula C6H11NO2; molecular weight 129.16) is a vinyl-GABA suicide inhibitor of GABA transaminase developed at Marion Merrell Dow and approved by the FDA in 2009 under the trade name Sabril (later than European registration in 1989). Mechanism: the vinyl group at the alpha-carbon converts vigabatrin into a substrate that the GABA transaminase enzyme begins to process but cannot release; the result is irreversible covalent enzyme inactivation, requiring de novo enzyme synthesis to recover GABA degradation capacity. The consequence is sustained elevation of brain GABA concentrations. Effective in infantile spasms (West syndrome) where conventional anticonvulsants often fail, and as adjunctive therapy in refractory complex partial seizures. The principal limitation is irreversible bilateral concentric visual field constriction in approximately 30 to 50 percent of long-term users, attributed to retinal photoreceptor damage; the FDA REMS program requires baseline and periodic visual field assessment. Plasma half-life is 5 to 13 hours, but the irreversible enzyme inhibition produces effective activity beyond the plasma window. Used as the canonical GABA transaminase suicide inhibitor.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-246Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lurasidone

Plain-language summaryIntrigue 67 / 100

Lurasidone (Latuda) is a Japanese atypical antipsychotic from Sumitomo Dainippon, approved by the FDA in 2010. It blocks dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors in roughly balanced fashion, with very little activity at histamine or muscarinic receptors. That receptor profile gives it the lowest metabolic burden of the atypical antipsychotic class: minimal weight gain, minimal lipid or glucose disturbance, and minimal sedation. The 5-HT7 antagonism appears to contribute distinct procognitive and antidepressant effects, which is why it is approved for both schizophrenia and bipolar depression. The catch is that absorption is highly food-dependent: it must be taken with at least 350 calories or it does not work properly. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

59/100

Reference 5-HT7 antagonist among approved antipsychotics with a clean metabolic and sedation profile

Look, lurasidone doesn’t show up in our library because it needs introduction. It’s Latuda. It’s been an approved atypical antipsychotic since 2010, used by millions of patients, and the core D2/5-HT2A story is as well-understood as anything in that class gets. The reason it earns a place here isn’t the receptor profile everyone already knows — it’s the 5-HT7 component, and specifically what that means for investigators trying to do clean receptor-level work in bipolar depression or cognitive-outcome models.

The 5-HT7 receptor is underappreciated. It’s a Gs-coupled receptor widely expressed in the SCN, thalamus, and limbic circuitry, implicated in circadian entrainment, mood regulation, and cognitive processing in ways the traditional D2 and 5-HT2A blockade story doesn’t fully explain. Lurasidone’s Ki at 5-HT7 sits around 0.5 nM — making it the most potent 5-HT7 antagonist among all approved antipsychotics in clinical use. That’s not a small thing. When you want to study 5-HT7 contribution to antidepressant effect in a system that also needs regulatory-grade pharmacokinetics and an established safety profile, lurasidone is the reference tool.

What we like is the selectivity shape. Minimal H1 activity means the sedation confound that wrecks olanzapine and quetiapine in any cognition paradigm is largely absent. Minimal muscarinic means no acetylcholine bleed-through in cholinergic-adjacent readouts. The 5-HT1A partial agonism adds complexity but also mirrors the profile of vilazodone, making cross-comparison useful in bipolar depression studies. The food-dependent absorption (roughly 350 kcal required) is an annoyance worth noting in preclinical translational design, and akathisia is the dose-limiting signal in clinical contexts.

Where it loses ground is novelty and bench ceiling. The compound is fifteen years old. The clinical literature for schizophrenia and bipolar I depression is well-replicated — multiple phase 3 trials, FDA approval, substantial real-world data — but that evidence base answers clinical questions, not mechanistic ones. If you want a clean 5-HT7 probe with no D2 confound, SB-269970 or SB-656104 are more selective research tools. Lurasidone’s value is translational: it’s what you reach for when you want to connect receptor-level findings back to a clinically-validated pharmacological context.

Thats the honest case for it. Not a frontier compound, not a workhorse for basic receptor characterization, but a well-validated clinical reference tool with the most potent 5-HT7 profile of anything approved. For investigators running bipolar depression models, circadian disruption paradigms, or cognitive-outcome studies where 5-HT7 contribution is the specific variable, it’s genuinely useful and not easily replaced by something better positioned.

Novelty

33

Mechanism promise

60

In-category differentiation

63

Evidence quality

78

Translational signal

72

Research bench value

52

Rationale Lurasidone holds its place as the most potent 5-HT7 antagonist in clinical use, with a selective receptor shape that limits sedation and metabolic confounds useful for cognition and mood paradigms; its 2010 approval and fully characterized mechanism keep novelty and differentiation modest, and the overall score reflects real but bounded bench utility as a translational tool rather than a frontier research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic with 5-HT7 antagonism

A benzisothiazole atypical antipsychotic with prominent 5-HT7 receptor antagonism contributing to procognitive and antidepressant effects.

Abstract

Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]-cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione; CAS 367514-87-2; molecular formula C28H36N4O2S; molecular weight 492.68) is a benzisothiazole atypical antipsychotic developed at Sumitomo Dainippon and approved by the FDA in 2010 under the trade name Latuda. The receptor profile features full D2 antagonism (Ki approximately 1 nM), potent 5-HT2A antagonism (Ki approximately 0.5 nM), 5-HT1A partial agonism (Ki approximately 6.4 nM), and prominent 5-HT7 antagonism (Ki approximately 0.5 nM, the most potent in clinical use). The 5-HT7 antagonism is associated with procognitive effects and improvement in bipolar depression. H1 and muscarinic activity is minimal, producing low sedation and metabolic burden compared to olanzapine and quetiapine; the principal limitation is dose-related akathisia. Plasma half-life is 18 hours; absorption requires food (approximately 350 kcal). Metabolism is via CYP3A4. Approved for schizophrenia (acute and maintenance), bipolar I depression (monotherapy or with lithium/valproate). Used as the reference 5-HT7-prominent antipsychotic.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-238Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Risperidone

Plain-language summaryIntrigue 65 / 100

Risperidone (Risperdal) is the most prescribed atypical antipsychotic in the world. Janssen brought it to market in 1993 as the prototype of the combined dopamine D2 plus serotonin 5-HT2A blocker design that defined second-generation antipsychotics. Approved for schizophrenia, bipolar mania, and irritability in autism, it is also widely used off-label in dementia behavioral disturbance and various pediatric conditions. At low doses (1 to 2 mg) it acts more like a typical atypical; at higher doses (above 6 mg) the 5-HT2A advantage washes out and it produces extrapyramidal symptoms and prolactin elevation comparable to older haloperidol. Its active leftover is itself sold separately as paliperidone (Invega). Available as a long-acting injection (Risperdal Consta) for adherence support. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

The canonical D2/5-HT2A reference atypical: indispensable as a probe, not interesting as a discovery target

Look, risperidone is one of those compounds where the score almost writes itself. Approved in 1993, the most prescribed atypical antipsychotic on the planet, a metabolite (paliperidone) that got its own branded approval. The D2/5-HT2A dual antagonism profile was genuinely interesting when Janssen published it, but that was over thirty years ago, and the pharmacology has been beaten to death across thousands of studies. There is no open mechanism question here.

The receptor profile is textbook at this point: D2 at roughly 4 nM Ki, 5-HT2A at roughly 0.16 nM, a 25:1 ratio that drives the atypical character at low doses and collapses into something approaching haloperidol above 6 mg. The dose-EPS relationship is cited in every antipsychotic pharmacology lecture. The active metabolite contribution is fully characterized. The long-acting injectable formulations are mature commercial products. We’re not going to learn something new about risperidone by running another preclinical series on it.

Where it does hold up as a library entry is bench utility. If your lab is interrogating dopamine receptor biology, autism rodent models, antipsychotic-induced metabolic side effects, or the 5-HT2A / D2 interaction in prefrontal circuits, risperidone is the reference compound. Its well-characterized receptor kinetics and extensive pharmacokinetic database make it a reliable anchor for comparison studies. That’s not nothing. The bench value here is real, its just the value of a well-understood reference, not the value of a frontier probe.

Whats genuinely low here is novelty and mechanism promise. The combined D2/5-HT2A antagonist class is completely saturated. Aripiprazole took the partial agonist angle. Clozapine remains the efficacy benchmark with its messy multireceptor profile. Brexpiprazole and cariprazine refined the partial agonist story further. Risperidone sits as the prototype definition of the class, which means investigators in the field use it as a comparator, not an object of investigation. If you’re designing an experiment to answer a novel question about psychosis biology, risperidone is your control arm, not your experimental arm.

The evidence quality and translational scores are legitimately high. Three approved indications, multiple phase 3 programs, long-acting formulations with their own trial bases, decades of post-marketing surveillance. We’re not questioning the clinical reality. But the rubric asks whether a bench scientist should find this compound worth primary research time right now, and the honest answer is almost certainly no unless the goal is characterizing something new against a reliable reference. As a discovery target in 2025, risperidone is basically done.

Novelty

18

Mechanism promise

28

In-category differentiation

40

Evidence quality

82

Translational signal

75

Research bench value

65

Rationale Risperidone is a 1993-approved, fully characterized reference compound whose novelty and mechanism scores are floor-bound by three decades of settled pharmacology; evidence and translational scores are ceiling-bound by its FDA approval across three indications, but those high downstream scores can’t rescue the overall because the rubric weights novelty and mechanism heavily. Bench value is real but narrow: it scores meaningfully as a canonical probe for D2/5-HT2A biology, not as a frontier research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic

A benzisoxazole atypical antipsychotic; the most prescribed atypical worldwide and the prototype combined D2 / 5-HT2A antagonist.

Abstract

Risperidone (3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; CAS 106266-06-2; molecular formula C23H27FN4O2; molecular weight 410.49) is a benzisoxazole atypical antipsychotic developed at Janssen and approved by the FDA in 1993 under the trade name Risperdal. The receptor profile is the prototype combined D2/5-HT2A antagonist: D2 (Ki approximately 4 nM), 5-HT2A (Ki approximately 0.16 nM, ratio approximately 25:1 favoring 5-HT2A), with secondary alpha-1, alpha-2, and H1 antagonism. At doses below 6 mg the 5-HT2A predominates and EPS is minimal; above 6 mg the D2 antagonism produces dose-dependent EPS approaching haloperidol-like profile. The active metabolite 9-hydroxyrisperidone (paliperidone, marketed as Invega) carries similar receptor profile and contributes substantially to steady-state activity. Risperidone is the most prescribed atypical antipsychotic worldwide. Plasma half-life is 3 hours for parent, 24 hours for paliperidone metabolite. Long-acting injectables (Risperdal Consta, Perseris) provide biweekly or monthly administration. Approved for schizophrenia, bipolar mania, autism-associated irritability. Used as the canonical D2/5-HT2A reference atypical.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-239Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pimavanserin

Plain-language summaryIntrigue 72 / 100

Pimavanserin (Nuplazid) is the first FDA-approved drug for Parkinson disease psychosis, brought to market by ACADIA in 2016. It is also the first antipsychotic without any dopamine receptor activity at all, which makes it pharmacologically unique in its class. Mechanistically it is a selective 5-HT2A inverse agonist (it actively turns off the receptor’s baseline signaling rather than just blocking serotonin from binding). Because it leaves dopamine signaling alone, it does not worsen the motor symptoms of Parkinson disease the way standard antipsychotics do. The 2016 approval was politically contentious because mortality data in elderly trial patients was concerning, and a 2019 follow-up trial in dementia-related psychosis failed. Still in clinical use specifically for Parkinson psychosis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

64/100

The reference selective 5-HT2A inverse agonist; approved, well-evidenced, and a genuine research probe but no longer novel

Look, pimavanserin occupies a strange position in the research library. It’s an approved drug, which means the clinical evidence story is unusually clean for something you’d find in a peptide-adjacent catalog, and the mechanism is as elegant as anything in CNS pharmacology. But elegant and nine-years-old are two different things, and the novelty axis is where this compound gives ground.

The core story: ACADIA built a compound with essentially perfect selectivity for 5-HT2A (Ki ~0.087 nM) over everything else, and importantly over dopamine receptors entirely. D2 affinity above 1000 nM means it has no meaningful dopaminergic activity, which is the whole clinical insight. Parkinson disease psychosis is a therapeutic dead zone because every conventional antipsychotic that quiets hallucinations through D2 blockade will simultaneously aggravate motor symptoms. Pimavanserin sidesteps that entirely. Thats not a small pharmacological trick; it’s a genuinely useful dissection of what 5-HT2A signaling contributes versus what D2 blockade contributes in the psychotic state.

The inverse agonist distinction matters for bench work. Pimavanserin doesn’t just block 5-HT2A signaling, it reduces constitutive activity below baseline. If you’re asking what tonic 5-HT2A receptor activity does in a given circuit, simple antagonism can’t answer that cleanly. Pimavanserin can. We think that probe value is real and underappreciated in groups working on cortical 5-HT2A biology, psychedelic pharmacology (where 5-HT2A agonism is the mechanism of interest), and antipsychotic drug discovery.

Evidence is solid in the approved indication. Multiple phase 3 RCTs in PD psychosis, FDA approval in 2016, and a mature pharmacokinetic profile that investigators can work with (57-hour parent t1/2, 200-hour active metabolite, CYP3A4-driven metabolism). The supplemental NDA for Alzheimer’s disease psychosis was a setback: FDA rejected it in 2022 despite the HARMONY trial data, citing insufficient evidence of effect and the class black-box mortality signal. The MDD augmentation program is still live and there’s genuine mechanistic rationale there, but that pipeline is not yet definitive.

What we like: the selectivity profile is irreplaceable if you’re doing 5-HT2A receptor biology and need to avoid dopaminergic confounds. What we don’t like: the novelty window is mostly closed. The literature is deep enough that incremental new findings aren’t the frontier anymore. The Alzheimer’s program being paused removes the most compelling near-term indication expansion. For groups actively studying 5-HT2A function, psychedelic neuroscience, or antipsychotic mechanism, pimavanserin stays relevant as the reference tool. For everyone else, the 64 reflects that this is a well-understood, well-evidenced compound doing exactly what it was designed to do, with no serious surprises left in the mechanism.

Novelty

40

Mechanism promise

63

In-category differentiation

72

Evidence quality

72

Translational signal

72

Research bench value

72

Rationale Pimavanserin scores well on differentiation and bench value because it is the canonical selective 5-HT2A inverse agonist probe with no dopaminergic liability, making it irreplaceable for dissecting constitutive 5-HT2A signaling. Novelty pulls the composite down hard: FDA approval was 2016, mechanism is fully characterized, and the high-profile Alzheimer’s disease psychosis program was rejected by FDA in 2022, so the indication expansion story is cooler than the outcome.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective 5-HT2A inverse agonist

The first FDA-approved drug for Parkinson disease psychosis; a selective 5-HT2A inverse agonist with no dopamine receptor activity.

Abstract

Pimavanserin (1-[(4-fluorophenyl)methyl]-1-[(1-methyl-4-piperidinyl)methyl]-3-{4-[(2-methylpropoxy)]phenyl}urea; CAS 706779-91-1; molecular formula C25H34FN3O2; molecular weight 427.56) is a selective 5-HT2A inverse agonist developed at ACADIA and approved by the FDA in 2016 under the trade name Nuplazid. Distinct among antipsychotics by absence of dopamine receptor activity: D2 affinity is greater than 1000 nM, with no clinically relevant binding. Selectivity is for 5-HT2A (Ki approximately 0.087 nM) over 5-HT2C (Ki approximately 0.4 nM, approximately 5-fold selective). The compound is a high-efficacy inverse agonist (not merely an antagonist), reducing constitutive 5-HT2A signaling below baseline. The dopaminergically clean profile is uniquely suited to Parkinson disease psychosis, where conventional antipsychotics’ D2 antagonism worsens motor symptoms; pimavanserin treats hallucinations and delusions without aggravating bradykinesia or rigidity. Plasma half-life is 57 hours for parent compound, 200 hours for active metabolite. Metabolism is via CYP3A4 and CYP3A5. The compound carries an FDA black-box warning for increased mortality in elderly dementia patients (a class warning for all antipsychotics). Used as the reference selective 5-HT2A inverse agonist.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-240Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sodium Valproate

Plain-language summaryIntrigue 71 / 100

Sodium valproate (Depakote, in the divalproex form) is a deceptively simple molecule (a branched fatty acid) that turned out to do an extraordinary number of useful things in the brain: block voltage-gated sodium channels, raise GABA levels by inhibiting GABA transaminase, block T-type calcium channels, and inhibit histone deacetylases. Originally noticed in 1962 as a bioactive compound while serving as a solvent in pharmacology screening, it was approved by the FDA in 1978 and remains a first-line anticonvulsant for generalized seizures, one of the two best mood stabilizers in bipolar disorder, and a workhorse for migraine prevention. It is highly teratogenic (causes severe birth defects) and women of childbearing potential should generally avoid it. Liver toxicity, pancreatitis, and weight gain are notable. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

A mature broad-spectrum anticonvulsant with strong evidence but minimal frontier research value today

Honestly, sodium valproate is one of the clearest examples of a compound where the evidence score and the novelty score pull in completely opposite directions. It was discovered accidentally in 1962 while serving as a solvent during pharmacological screening in Lyon, approved by the FDA in 1978, and has since generated more replicated clinical data than most compounds in this library combined. That evidence quality counts for something. It just doesn’t make it an interesting research target right now.

The mechanism is genuinely multifactorial, and thats worth acknowledging. GABA transaminase inhibition, voltage-gated sodium channel blockade, T-type calcium channel modulation, and histone deacetylase inhibition all operate simultaneously in a way that’s unusual for a simple branched-chain fatty acid. The HDAC angle is actually why valproate still shows up in serious research programs at all. It’s one of the only clinically approved HDAC inhibitors with decades of human pharmacokinetic and pharmacodynamic data behind it, which gives it a specific translational utility that purely preclinical tools don’t replicate. Researchers studying VPA’s epigenetic effects in glioblastoma combination regimens, ALS neuroprotection, or neuronal reprogramming protocols have a concrete reason to reach for it specifically.

But here’s the thing: if you’re running a precise HDAC inhibitor probe program, you’re probably using vorinostat, romidepsin, or a class-selective tool like entinostat, not valproate. The selectivity profile isn’t favorable for clean mechanistic dissection across HDAC subtypes. And if you’re studying anticonvulsant pharmacology, levetiracetam and lacosamide have displaced it as the more technically interesting targets in most contemporary programs. Valproate shows up in combination studies or as a reference standard, not as the primary object of investigation.

The teratogenicity history is also a real practical constraint. The regulatory environment around valproate and fetal exposure has become increasingly restrictive, particularly in Europe, and that context follows the compound into research discussions even where it’s technically irrelevant. The hepatotoxicity and hyperammonemia signals add to the handling picture.

What we like: the reference standard status is real and not nothing. Translational signal is strong almost by definition for an approved drug with three approved indications. The HDAC-in-CNS-disease literature generates actual publications in serious journals, and any bench program in neuroepigenetics should know this compound’s profile well.

What we don’t like: there’s very little left to discover. The mechanism is well-mapped. The clinical profile is settled. The research community studying this compound isn’t growing, and the novel angles that do exist are better pursued with more selective modern tools. Solid reference compound. Not a frontier target.

Novelty

18

Mechanism promise

42

In-category differentiation

38

Evidence quality

82

Translational signal

78

Research bench value

65

Rationale Valproate scores high on evidence and translational signal because it’s an approved drug with decades of replicated clinical data across multiple indications, but novelty is near-floor for a compound discovered in 1962 and approved in 1978. The HDAC inhibition angle is the only thing that keeps mechanism and bench-value from bottoming out, and even that story has been partially superseded by more selective HDACi tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Branched-chain fatty acid anticonvulsant / mood stabilizer

A simple branched-chain fatty acid with broad anticonvulsant activity and mood-stabilizing efficacy in bipolar disorder.

Abstract

Sodium valproate (sodium 2-propylpentanoate; CAS 1069-66-5; molecular formula C8H15NaO2; molecular weight 166.20) is a branched-chain fatty acid anticonvulsant first characterized as bioactive in 1962 (incidentally, while serving as a solvent in pharmacological screening at Lyon). Approved by the FDA in 1978 (Depakote, the divalproex sodium delayed-release form). Mechanism is multifactorial: GABA transaminase inhibition increases brain GABA; sodium channel blockade reduces neuronal hyperexcitability; T-type calcium channel inhibition supports anti-absence activity; histone deacetylase (HDAC) inhibition modifies gene expression with neuroprotective and possibly disease-modifying implications in bipolar disorder. Plasma half-life is 9 to 16 hours; metabolism is via beta-oxidation, omega-oxidation, and glucuronidation. Approved indications include all major seizure types (partial, generalized tonic-clonic, absence, myoclonic), bipolar I disorder mania, and migraine prophylaxis. The principal limitation is teratogenicity (neural tube defects, cognitive deficits in offspring) requiring strict avoidance in pregnancy and women of childbearing age. Hepatotoxicity, pancreatitis, and hyperammonemia are recognized adverse events. Used as the canonical broad-spectrum anticonvulsant and HDAC inhibitor reference.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-242Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Buspirone

Plain-language summaryIntrigue 60 / 100

Buspirone (BuSpar) is the first non-benzodiazepine anxiolytic, approved by the FDA in 1986. Mechanistically it is unrelated to any sedative class: it is a partial agonist at the serotonin 5-HT1A receptor, with no GABA-A activity. That means it does not produce sedation, dependence, or withdrawal, and it has no recreational potential. The trade-off is that it works slowly (effects build over 2 to 4 weeks) and does not produce the fast acute relief patients expect from a benzodiazepine, which has limited its uptake despite its safety advantages. It is FDA-approved for generalized anxiety disorder and is widely used as add-on for SSRI-treated depression where some additional anxiolysis is needed. The active metabolite 1-PP is an alpha-2 antagonist contributing to the noradrenergic tone. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Canonical 5-HT1A probe, mature anxiolytic with real evidence but thin novelty in 2026

Look, buspirone is a compound that was genuinely interesting in 1986. The first non-benzodiazepine anxiolytic approved by the FDA, it demonstrated that you could hit generalized anxiety disorder through 5-HT1A partial agonism rather than GABA-A potentiation, and that doing so meant no sedation, no tolerance, no physical dependence. For its era, that was a meaningful pharmacological statement. The mechanism story around autoreceptor desensitization, where the delayed anxiolytic onset (two to four weeks) reflects slow downregulation of presynaptic 5-HT1A somatodendritic autoreceptors, remains instructive for anyone studying serotonin system kinetics. The 1-PP metabolite’s alpha-2 antagonism adds a noradrenergic wrinkle that still gets cited in systems-level work.

The problem is that we’re rating research merit in 2026, not 1986. The 5-HT1A partial agonist mechanism is thoroughly mapped. There are no hidden pockets in this pharmacology waiting to be discovered by a bench investigator picking up buspirone today. Its Ki of approximately 21 nM and intrinsic activity around 35 percent are numbers that have appeared in textbooks for decades. Secondary D2 antagonism at roughly 100 nM is real but the clinical significance remains unclear after forty years of trying to pin it down. Thats not the profile of a compound that’s going to generate an interesting paper in 2026 unless you’re specifically using it as a reference probe.

And that’s honestly where buspirone still earns its keep. As the canonical 5-HT1A partial agonist, it is the go-to tool compound when you need to isolate this receptor’s contribution to a behavioral or neurochemical readout. Comparing full agonists, partial agonists, and antagonists at 5-HT1A? You’re reaching for buspirone. Disentangling 5-HT1A from 5-HT1B or 5-HT2A contributions in a circuit-level experiment? Buspirone is in the protocol. That probe value is real, particularly in translational anxiety models or serotonin-system interaction studies. It’s not a replacement for newer tools, but it’s not obsolete either.

What we don’t find compelling is the idea of prioritizing buspirone as a primary research target. Its evidence base is among the strongest in this library, multiple phase 3 RCTs, decades of replicated mechanism work, FDA approval since Reagan’s second term. But that evidence bulk is exactly the problem: the question has been answered. GAD pharmacology has moved on to SSRIs, SNRIs, and increasingly ketamine and psychoplastogen-adjacent compounds as the interesting frontier. Buspirone sits comfortably in the literature as a mature reference standard with modest differentiation from newer anxiolytics on actual clinical metrics. Score it accordingly.

Novelty

22

Mechanism promise

30

In-category differentiation

35

Evidence quality

72

Translational signal

65

Research bench value

60

Rationale Buspirone earns its score almost entirely from evidence quality, translational signal, and residual bench utility as the reference 5-HT1A partial agonist; novelty and mechanism promise are dragged down by 40 years of literature and a single-receptor story that the field has well characterized. No scheduling or category cap applies, but the raw calculation lands squarely in established-mature territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist anxiolytic

An azapirone 5-HT1A partial agonist; a non-benzodiazepine anxiolytic without dependence or sedation.

Abstract

Buspirone (8-[4-(4-pyrimidin-2-yl-1-piperazinyl)butyl]-8-azaspiro[4.5]decane-7,9-dione; CAS 36505-84-7; molecular formula C21H31N5O2; molecular weight 385.50) is an azapirone 5-HT1A partial agonist developed at Bristol-Myers Squibb and approved by the FDA in 1986 under the trade name BuSpar. The compound is the first clinically approved non-benzodiazepine anxiolytic, distinguished by mechanism (5-HT1A partial agonism rather than GABA-A potentiation), tolerance/dependence profile (none), and absence of sedation. 5-HT1A affinity is approximately 21 nM (intrinsic activity approximately 35 percent); secondary D2 antagonism (Ki approximately 100 nM) is of unclear clinical significance. The active metabolite 1-(2-pyrimidinyl)piperazine (1-PP) is an alpha-2 adrenergic antagonist contributing to noradrenergic effects. Onset of anxiolytic effect is delayed (2 to 4 weeks), reflecting the time course of 5-HT1A autoreceptor desensitization. Plasma half-life is 2 to 3 hours; metabolism is extensive via CYP3A4 with significant first-pass effect (oral bioavailability approximately 4 percent). Approved for generalized anxiety disorder. Used as the canonical 5-HT1A partial agonist in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-248Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lamotrigine

Plain-language summaryIntrigue 72 / 100

Lamotrigine (Lamictal) is a clean voltage-gated sodium channel blocker from GSK, approved by the FDA in 1994 for partial seizures and now equally important as a first-line mood stabilizer for bipolar depression and bipolar maintenance. It is unusual in mood medicine because, unlike lithium and valproate, it is more effective at preventing depressive episodes than manic ones. The mechanism is state-dependent: it preferentially binds inactivated sodium channels, which selectively dampens hyperactive neurons while leaving normal firing alone. The infamous risk is Stevens-Johnson syndrome (potentially fatal skin reaction) if titrated too quickly, which is why the dose-up schedule is conservative and stretched over weeks. Otherwise it is one of the most metabolically clean drugs in psychiatry. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

52/100

Mature VGSC blocker with uniquely differentiated bipolar depression profile and real but aging bench utility

Here’s the thing about lamotrigine: it’s one of the more mechanistically interesting anticonvulsants on paper, but it’s been around since 1994, and that age dominates the novelty picture. The core mechanism, state-dependent inhibition of voltage-gated sodium channels with preferential binding to the inactivated state, is thoroughly mapped. The downstream story, reduced presynaptic release of glutamate and aspartate, is well-understood. Secondary high-voltage-activated calcium channel inhibition and weak 5-HT3 antagonism add texture to the profile, but none of that is new territory for anyone working in this space.

What we actually find interesting about lamotrigine in a research context is the bipolar depression dissociation. Most mood stabilizers, lithium being the reference, are clearly better at suppressing mania than preventing depressive episodes. Lamotrigine inverts that relationship: the Calabrese et al. phase 3 maintenance datasets and the GSK registration trials established repeatedly that it’s primarily effective on the depressive pole. That asymmetry is real, replicated, and the mechanistic explanation for it remains genuinely open. If you’re studying the neuropharmacology of depression versus mania at the circuit or sodium channel isoform level, that gap is where the bench value lives.

As a pharmacological probe, lamotrigine is one of the cleaner VGSC tools available. Glucuronidation-dominated metabolism means fewer CYP2 interactions than carbamazepine or phenytoin, making it more tractable in multi-compound studies. For investigators working on glutamatergic excitability, firing-frequency-dependent channel pharmacology, or sodium channel isoform selectivity questions, its probe value is legitimate. It’s not indispensable in the way rapamycin is to mTOR work, but its clean metabolic profile and well-characterized kinetics make it useful in the right experimental context.

The honest constraint here is that theres not much frontier left. The mechanism is characterized to the point where a new bench scientist will find more questions answered than open. Clinical pharmacology is fully mapped. The rash and Stevens-Johnson liability, while manageable with slow titration in clinical settings, introduces real constraints in certain model systems. Patent expiry is ancient history. The compound does what it does very well, and the bipolar depression angle keeps it genuinely differentiated from lithium and valproate, but that differentiation is now a clinical fact rather than an active research question for most groups.

We score lamotrigine at 52: solidly useful in the right hands, genuinely differentiated on one clinical dimension, backed by strong evidence, but held back by age and thorough characterization. A researcher who specifically needs a state-dependent VGSC blocker or who is working on the bipolar depression mechanism question will find it indispensable. For general prioritization in a research library, it belongs in the catalog as a reference compound rather than a priority target.

Novelty

22

Mechanism promise

35

In-category differentiation

55

Evidence quality

82

Translational signal

78

Research bench value

58

Rationale Lamotrigine earns a mid-range score because the bipolar depression dissociation from the mania-dominant mood stabilizer class is genuinely differentiated and the evidence base is phase-3 strong; novelty and mechanism scores pull it down hard since the compound is fully characterized, decades off-patent, and there is no meaningful frontier science left in the core pharmacology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenyltriazine sodium channel blocker / mood stabilizer

A phenyltriazine voltage-gated sodium channel blocker; uniquely effective for bipolar depression and a first-line maintenance mood stabilizer.

Abstract

Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; CAS 84057-84-1; molecular formula C9H7Cl2N5; molecular weight 256.09) is a phenyltriazine voltage-gated sodium channel blocker developed at Wellcome (now GSK) and approved by the FDA in 1994 under the trade name Lamictal. Mechanism: state-dependent inhibition of voltage-gated sodium channels (preferentially binding inactivated state), reducing release of presynaptic glutamate and aspartate. Secondary inhibition of high-voltage-activated calcium channels and weak antagonism at 5-HT3 receptors contribute to the broader profile. Distinct among anticonvulsants for efficacy in bipolar depression and maintenance mood stabilization (more effective at preventing depressive than manic episodes, opposite the lithium pattern). Plasma half-life is 25 to 33 hours alone, shortened by enzyme-inducing comedications. Hepatic metabolism is primarily glucuronidation. The principal limitation is a benign rash incidence of approximately 10 percent and Stevens-Johnson syndrome at approximately 1 in 1000, both reduced by slow titration over 4 to 6 weeks. Approved for partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and bipolar I disorder maintenance. Used as the reference anticonvulsant mood stabilizer and as a clean voltage-gated sodium channel blocker.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-243Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Carbamazepine

Plain-language summaryIntrigue 60 / 100

Carbamazepine (Tegretol) is a first-generation anticonvulsant from Geigy, synthesized in 1953 and FDA-approved in 1968. It blocks voltage-gated sodium channels much like lamotrigine and is broadly effective for partial seizures, trigeminal neuralgia (where it is first-line), and bipolar mania. Its big practical headache is potent induction of the liver enzyme CYP3A4, which means it accelerates the breakdown of many other drugs (oral contraceptives, warfarin, many antidepressants), creating constant interaction problems. It also induces its own metabolism, so doses often need to climb in the first few weeks. The active leftover is a structurally similar epoxide that contributes to both the therapeutic effect and the side effects. Aplastic anemia and Stevens-Johnson syndrome are rare but serious risks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

First-generation sodium channel blocker, proven and approved, long superseded as a novel research target

Look, carbamazepine is a 70-year-old drug that works. The mechanism, state-dependent voltage-gated sodium channel inhibition, was characterized decades ago and hasn’t gotten more interesting since. What carbamazepine does best is be reliable, and that reliability is precisely what limits its appeal as a live research target in 2024.

The evidence base is genuinely impressive, in the way that things that have been FDA-approved since 1968 tend to be. Hundreds of replicated trials for partial-onset seizures, tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania. The translational arrow points straight down from bench to clinic because that work was done half a century ago. We’re not learning new things about carbamazepine; we’re using what we already know.

The differentiation story is the hard part. Oxcarbazepine was developed specifically to strip out carbamazepine’s worst liabilities, the potent CYP3A4 induction that wrecks contraceptive coverage and immunosuppressant dosing, the aplastic anemia and agranulocytosis risk, the SJS/TEN exposure in HLA-B*1502 carriers. Lacosamide took the sodium channel story in a more selective direction with slow-inactivation preference. Lamotrigine achieved a cleaner dual-mechanism profile with a better tolerability envelope. Carbamazepine retains the reference iminostilbene label, and thats genuinely useful for comparative class pharmacology. But if youre designing a new research program on voltage-gated sodium channels, you probably dont open with this one.

Honestly, where it still earns real bench credit is narrow but real. The auto-induction kinetics are a legitimate research model: the half-life collapses from 25-65 hours at first dose to 12-17 hours at steady state as it induces its own CYP3A4-mediated clearance, which makes it one of the cleaner in vivo models for studying auto-induction biology. The HLA-B*1502 pharmacogenomics work around SJS/TEN prediction in East and Southeast Asian populations is live research, and carbamazepine is the reference exposure for those studies. Those are real questions. They’re just not the kind of questions that drive high-priority bench allocations.

We think this belongs in the library as a reference standard and a pharmacogenomics model, not as a compound with active research momentum. A serious investigator looking for fresh signal in sodium channel pharmacology, CNS excitability, or mood stabilization would not prioritize carbamazepine in 2024. The science is largely settled. The score reflects that.

Novelty

12

Mechanism promise

20

In-category differentiation

28

Evidence quality

78

Translational signal

72

Research bench value

45

Rationale Carbamazepine scores high on evidence and translational signal because it is a fully approved drug with massive clinical literature, but novelty and mechanism promise are floor-level for a 1953 compound with a well-mapped, single-channel mechanism that newer agents have largely refined away. The reference probe angle gives it modest bench value, but this is not a compound generating new science.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Iminostilbene voltage-gated sodium channel blocker

A first-generation iminostilbene anticonvulsant and mood stabilizer with potent CYP3A4 induction.

Abstract

Carbamazepine (5H-dibenzo[b,f]azepine-5-carboxamide; CAS 298-46-4; molecular formula C15H12N2O; molecular weight 236.27) is an iminostilbene anticonvulsant developed by Walter Schindler at Geigy in 1953 and approved by the FDA in 1968 under the trade name Tegretol. Mechanism: state-dependent voltage-gated sodium channel inhibition (similar to lamotrigine), producing reduced neuronal hyperexcitability in seizure foci. Active metabolite carbamazepine-10,11-epoxide retains anticonvulsant activity. Plasma half-life is 25 to 65 hours initially but auto-induces own metabolism, dropping to 12 to 17 hours at steady state. Strong CYP3A4 induction produces clinically significant interactions with hormonal contraception, immunosuppressants, anticoagulants, antiretrovirals, and many other drugs. Approved for partial-onset and generalized tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania (in combination products). The principal safety concerns are aplastic anemia and agranulocytosis (rare but serious; HLA-B*1502 association predicts SJS/TEN risk in Asian populations and is screened pretreatment). Used as the reference iminostilbene voltage-gated sodium channel blocker.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-244Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tiagabine

Plain-language summaryIntrigue 50 / 100

Tiagabine (Gabitril) is a selective inhibitor of the GAT-1 GABA transporter, the protein that pulls GABA back into nerve cells after release. By blocking GAT-1, the drug prolongs the time GABA remains in the synapse and amplifies inhibitory signaling. It was approved by the FDA in 1997 as add-on therapy for partial seizures. Clinical adoption was modest because it does not work well as monotherapy and has a narrow effective dose window. It saw some off-label use for anxiety and sleep, but a paradoxical risk of inducing seizures in patients without epilepsy when used at off-label doses earned it an FDA warning in 2005. Mostly a research tool now for studying GABA transporter pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

51/100

Canonical GAT-1 probe with solid bench utility but negligible novelty as a discovery target

Look, tiagabine is one of those compounds that earns its place in a research library not because anyone is racing to study it, but because you cant study GAT-1 biology without it. Thats the whole story. Developed at Novo Nordisk and approved by the FDA in 1997 under the name Gabitril, its been the canonical selective GAT-1 inhibitor for nearly three decades. The selectivity profile is genuinely impressive: greater than 100-fold preference for GAT-1 over GAT-2 and GAT-3. That kind of selectivity makes it the reference standard when you need to isolate GAT-1-dependent GABA reuptake from the rest of the transporter family.

What we like mechanistically is the specificity. GAT-1 is the dominant neuronal reuptake transporter, and tiagabine lets you ask precise questions about phasic versus tonic inhibition, about extracellular GABA pooling, about slow-wave sleep induction. Vyazovskiy and colleagues have used it productively in sleep slow-wave amplitude work. That’s real bench value. It’s not flashy, but it’s the kind of probe that generates clean, interpretable data in the right hands.

Here’s the thing though: the research-excitement case is weak. The mechanism is mature and single-target. GAT-1 inhibition is not a new idea; its not a dual mechanism, not a mitochondrial angle, not tied to any of the hot current targets in metabolic, longevity, or neuroplasticity research. You know exactly what youre getting, which is the point for tool use and a liability for frontier research. Nobody is writing a grant in 2026 with tiagabine as the exciting part of the story.

The translational picture is mixed. In epilepsy it works, thats settled, approved, replicated across phase 3. The off-label anxiety angle is genuinely complicated. The FDA issued warnings about new-onset seizures at off-label doses, with roughly a 1 percent incidence in non-epileptic patients. That safety signal killed most of the off-label enthusiasm and limits how freely investigators can extrapolate findings. It doesnt make it unusable in research, but it does mean translational upside outside the seizure indication is constrained.

We think tiagabine belongs in any library that takes GABA transporter biology seriously. It’s not a compound you pitch to a study section as exciting; it’s a compound you pull off the shelf when your experimental design requires isolating GAT-1 function. Useful, established, non-redundant in its specific niche. The score reflects that exactly: not a destination, but an indispensable tool for investigators working in the space.

Novelty

22

Mechanism promise

38

In-category differentiation

58

Evidence quality

72

Translational signal

65

Research bench value

72

Rationale Tiagabine scores on the strength of its unique probe identity as the only widely-used GAT-1-selective inhibitor, but its 1997 approval date, well-trodden mechanism, and seizure-risk liability in off-label use drag novelty and translational scores down hard. The high differentiation and bench-value scores reflect its irreplaceable role in GABA transporter work, not research excitement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GAT-1 selective GABA reuptake inhibitor

A nipecotic acid derivative selective GABA reuptake inhibitor; the prototype GAT-1 transporter blocker.

Abstract

Tiagabine ((R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid; CAS 115103-54-3; molecular formula C20H25NO2S2; molecular weight 375.55) is a nipecotic acid derivative selective inhibitor of the GABA transporter GAT-1, developed at Novo Nordisk and approved by the FDA in 1997 under the trade name Gabitril. Mechanism: high-affinity inhibition of GAT-1 (the principal neuronal GABA reuptake transporter) prolongs synaptic GABA availability after release, enhancing GABA-A and GABA-B receptor activation. Selectivity for GAT-1 over GAT-2 and GAT-3 is greater than 100-fold. Plasma half-life is 7 to 9 hours; metabolism is via CYP3A4. Approved as adjunctive therapy in partial-onset seizures in patients aged 12 and older. Off-label use in generalized anxiety disorder has been complicated by FDA warnings of new-onset seizures in patients without epilepsy (incidence approximately 1 percent at off-label doses). Used as the canonical GAT-1 selective inhibitor in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-247Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Topiramate

Plain-language summaryIntrigue 68 / 100

Topiramate (Topamax) is a sugar-derived anticonvulsant from Johnson and Johnson, approved by the FDA in 1996. It hits multiple targets at once: blocks sodium channels, potentiates GABA-A receptors, blocks AMPA glutamate receptors, and inhibits carbonic anhydrase. The mechanistic breadth makes it useful well beyond epilepsy. It is approved for migraine prevention, where it is one of the more effective options. It has substantial off-label use for weight loss because the carbonic anhydrase inhibition produces a metallic taste that suppresses appetite, and for alcohol use disorder where it appears to reduce craving. The side effect signature includes word-finding difficulty (the patient slang is dopamax), tingling in hands and feet, and kidney stone risk. Co-formulated with phentermine as Qsymia for obesity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

Mature multifactorial anticonvulsant with real but narrowly concentrated bench utility in AMPA and glutamate programs

Look, topiramate is a compound that’s been around long enough to earn a nickname. “Dopamax” is what clinicians call it, a reference to the cognitive blunting that causes roughly 40 percent of patients to report word-finding difficulty and slowed mentation. That reputation didnt develop in a vacuum, and it tells you something real about what you’re working with when you put this molecule into a CNS research program.

What we actually find interesting isnt what a prescriber finds interesting. The five-target mechanism, state-dependent sodium channel inhibition, GABA-A potentiation at a non-benzodiazepine site, AMPA/kainate glutamate receptor antagonism, carbonic anhydrase inhibition across isozymes II and IV, and high-voltage calcium channel block, is genuinely unusual for a small molecule. You can source sodium channel blockers easily. GABA-A modulators are everywhere. The AMPA/kainate piece is the angle worth paying attention to, because topiramate remains one of the more pharmacologically accessible probes for AMPA receptor biology available to bench investigators. That has kept it relevant in CNS research programs even as its clinical novelty evaporated.

The evidence quality is not in question. Multiple phase 3 programs, FDA approval across four distinct indications, and decades of multi-site clinical data from populations in the tens of thousands. You dont have to speculate about whether topiramate produces a human signal. The question is whether the signal is interesting, and in most indications the answer is now mostly historical. The weight loss angle was differentiated in the Qsymia era, but GLP-1s have reframed that entire conversation and topiramate isnt competing there anymore.

The one area where current research still generates real signal is alcohol use disorder. Several controlled trials have shown suppression of craving and reduction in heavy drinking days, and the proposed mechanism, glutamatergic dampening of cue-induced salience, is both plausible and relatively underexplored compared to the naltrexone/acamprosate playbook. If your program touches AUD neuroscience or glutamate-driven compulsive behavior, topiramate is worth taking seriously as a reference compound with replicated human data.

We think the bench value is genuine but specific. If the program involves AMPA receptor pharmacology, CNS carbonic anhydrase biology, or glutamatergic contributions to addictive behavior, topiramate earns its place. For anything outside those domains, the cognitive liability and the largely-harvested literature make it a low-priority entry. Score of 50 reflects that kind of concentrated, real-but-narrow research utility: not a frontier compound, not a throwaway.

Novelty

22

Mechanism promise

45

In-category differentiation

45

Evidence quality

75

Translational signal

70

Research bench value

55

Rationale Topiramate’s unusually broad five-target mechanism and robust FDA-backed evidence base are real, but 30 years of thorough characterization suppresses novelty to the floor; the score reflects a compound whose research value is genuine but domain-specific, not frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sulfamate-substituted monosaccharide / multifactorial anticonvulsant

A sulfamate-substituted monosaccharide anticonvulsant with broad mechanism (sodium channels, GABA-A potentiation, AMPA antagonism, carbonic anhydrase inhibition); used for migraine prophylaxis and weight loss.

Abstract

Topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; CAS 97240-79-4; molecular formula C12H21NO8S; molecular weight 339.36) is a sulfamate-substituted monosaccharide anticonvulsant developed at Johnson and Johnson and approved by the FDA in 1996 under the trade name Topamax. Mechanism is multifactorial: state-dependent sodium channel inhibition; GABA-A receptor potentiation at a non-benzodiazepine site; AMPA/kainate glutamate receptor antagonism; carbonic anhydrase inhibition (isozymes II and IV); high-voltage calcium channel inhibition. The carbonic anhydrase activity contributes to the characteristic adverse events: paresthesias (40 percent of patients), nephrolithiasis (1.5 percent), metabolic acidosis. Cognitive side effects are pronounced: word-finding difficulty, slowed mentation. Plasma half-life is 21 hours; metabolism is approximately 70 percent renal excretion unchanged. Approved for partial-onset and generalized tonic-clonic seizures, Lennox-Gastaut syndrome, migraine prophylaxis, and (with phentermine, as Qsymia) chronic weight management. Used as the canonical multifactorial anticonvulsant and as a reference carbonic anhydrase inhibitor in CNS pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-245Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 36 37 38 39 40 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.